News

Dreem 3S is the first sleep wearable with an FDA-authorized Predetermined Change Control Plan.

The November Month in Review features a set of dermatology news coverage highlights, including FDA news and developments in psoriasis.

Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

As announced by NovelMed on December 2, 2024, the FDA has granted IND clearance for Ruxoprubart to commence an efficacy trial for the treatment of IgAN.

This portion of the latest Lungcast episode includes a discussion of therapies, triggers, and management of AERD.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Insufficient ferric carboxymaltose dosing and timing fail to significantly improve hemoglobin levels, suggesting gaps in perioperative anemia management.

During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.

A study found patients with schizophrenia exhibiting violence, vs. those who don’t, have less gray matter volume in the frontal lobe and greater thyroid-stimulating hormone levels.

Test your knowledge of the 2024 AASLD Practice Guidelines on blood- and imaging-based noninvasive liver disease assessment with this clinical quiz!

These findings indicate that incorporating educational video materials for psoriasis improved engagement in the shared decision-making process.

Test your knowledge of the AASLD NAFLD Practice Guidance and its clinical application in light of the new MASLD nomenclature.

ONS-5010 missed the pre-specified non-inferiority endpoint set with the FDA, but Outlook Therapeutics plans to resubmit the BLA in Q1 of 2025.

David G. Armstrong, DPM, PhD, and Michael S. Conte, MD discuss Phase 2 results on anatomically directed lower extremity gene therapy for ulcer healing.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

Hirschfield describes the need for therapies that address itch in PBC and explains what linerixibat, an IBAT inhibitor, may offer for pruritus.